WO1995033729A1 - Serotonin 5-ht1a and dopamin d2 receptor ligands - Google Patents

Serotonin 5-ht1a and dopamin d2 receptor ligands Download PDF

Info

Publication number
WO1995033729A1
WO1995033729A1 PCT/DK1995/000229 DK9500229W WO9533729A1 WO 1995033729 A1 WO1995033729 A1 WO 1995033729A1 DK 9500229 W DK9500229 W DK 9500229W WO 9533729 A1 WO9533729 A1 WO 9533729A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
phenyl
alkyl
cycloalkyl
hydrogen
Prior art date
Application number
PCT/DK1995/000229
Other languages
French (fr)
Inventor
Jens Kristian Perregaard
Ejner Knud Moltzen
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI9530429T priority Critical patent/SI0770066T1/en
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Priority to AU27322/95A priority patent/AU686400B2/en
Priority to EP95922420A priority patent/EP0770066B1/en
Priority to RU97100172A priority patent/RU2140920C1/en
Priority to PL95317530A priority patent/PL180847B1/en
Priority to DE69517027T priority patent/DE69517027T2/en
Priority to BR9507930A priority patent/BR9507930A/en
Priority to NZ288180A priority patent/NZ288180A/en
Priority to DK95922420T priority patent/DK0770066T3/en
Priority to JP8500193A priority patent/JPH10500959A/en
Priority to SK1549-96A priority patent/SK281646B6/en
Priority to AT95922420T priority patent/ATE193016T1/en
Publication of WO1995033729A1 publication Critical patent/WO1995033729A1/en
Priority to NO965183A priority patent/NO308534B1/en
Priority to FI964897A priority patent/FI964897A0/en
Priority to US09/424,930 priority patent/US6514993B1/en
Priority to HK97102506A priority patent/HK1000877A1/en
Priority to GR20000401802T priority patent/GR3034105T3/en
Priority to US10/334,481 priority patent/US20030120070A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms

Definitions

  • Serotonin 5-HTIA and dopamin D 2 receptor ligands Serotonin 5-HTIA and dopamin D 2 receptor ligands.
  • the present invention relates to a novel series of 4-phenylpiperazines, 4-phenyl- piperidines and 4-phenyl-1 ,2,3,6-tetrahydropyridines. Having effects on both central serotonin 5-HT-IA and dopamine D receptors, the novel compounds are useful in the treatment of certain psychic and neurologic disorders.
  • EP A1 0376607 relates to certain 1-[4-(3-indolyl)butyl]-4-(2-oxyphenyl)piperazine compounds being partial 5-HT-IA agonists.
  • EP A1 0526434 among a number of other compounds, describes 1 -[(4-phenyl- piperazin-1 -yl)-C2-6 alkyl]-benzimidazol-2-one compounds said to show 5-HTIA agonistic activity and 5-HT 2A antagonistic activity.
  • US Patent No 3,374,237 discloses a class of 1-phenyl-3-(4-phenyl-1-piperazinyl- C 2 - 4 alkyl)-2-imidazolidinones claimed to be useful as tranquilizers. No test data at all are presented.
  • AU Patent No 15658/83 discloses 3-(4-phenyl-1-piperazinyl-C 2 - alkyl)hydantoin compounds having antihypertensive effects.
  • WO 92/00282 relates to a subgroup of the compounds of US Patent No 3,374,237 which are 1-phenyl-3-[4-(4-phenyl-1 -piperazinyl)-1-butyl]-2-imidazolidinones having an optional chloro atom in the 2-position of the phenyl substituent in 1 -position of the imidazolidinone ring and a methoxy or ethoxy substituent in the 2- and/or 3-posi- tion of the other phenyl substituent.
  • the compounds show dopaminergic effects.
  • 5-HTIA partial agonists such as e.g. buspirone, 8-[4-[4-(2- pyrimidyl)-1 -piperazinyl]butyl]-8-azaspiro[4,5]decane-7,9-dione, gepirone, 4,4-dime- thyl-1 -[4-[4-(2-pyrimidyl)-1-piperazinyl]butyl]-2,6-piperidinedione, and ipsapirone, 2- [4-[4-(2-pyrimidyl)-1 -piperazinyl]butyl]-1 ,2-benzothiazol-3(2H)-one-1 , 1 -dioxide, have shown that 5-HT-IA partial agonists are useful in the treatment of anxiety disorders such as generalised anxiety disorder, panic disorder, and obsessive compulsive disorder (Glitz, D. A., Pohl, R., Drugs 1991 , 41, 11).
  • 5-HT-IA agonists and partial agonists inhibit isolation-induced aggression in male mice indicating that these compounds are useful in the treatment of aggression (Sanchez et al., Psychopharmacology, 1993, 110, 53-59).
  • 5-HT-IA agonists have been reported to show antipsychotic effect in animal models (Wadenberg and Ahlenius, J. Neural. Transm., 1991 , 83, 43; Ahlenius, Pharmacol.&Toxicol., 1989, 64, 3; Lowe et al., J. Med. Chem., 1991 , 34, 1860; New et al., J. Med. Chem., 1989, 32, 1147;and Martin et al., J. Med.
  • 5-HT 1A receptors are impor ⁇ tant in the serotonergic modulation of haloperidol-induced catalepsy (Hicks, Life Science 1990, 47, 1609, Wadenberg et al. Pharmacol. Biochem. & Behav. 1994, 47, 509-513) suggesting that 5-HT-
  • EPS extrapyramidal side effects
  • DA receptor blocking drugs Damping of dopamine (DA) overactivity by the use of DA receptor blocking drugs is today the most important principle in the treatment of schizophrenia, in particular the ⁇ o positive symptoms thereof, and other psychoses.
  • "Classical neuroleptics" such as haloperidol, cis(Z)-flupentixol and chlorpromazine are believed to induce antipsy ⁇ chotic effect via DA receptor blockade.
  • EPS et et al. Neuropharmacology, 1981 , 20,
  • 5-HT-IA agonists have shown neuroprotective properties in rodent 20 models of focal and global cerebral ischaemia and may, therefore, be useful in the treatment of ischaemic disease states (Prehn , Eur. J. Pharm. 1991 , 203, 213).
  • 5-HT-IA agonists exert antihypertensive effects via a central mechanism (Saxena and Villal ⁇ n, Trends Pharm. Sci. 1990, 11, 95; Gillis et al, J. Pharm. Exp. Ther. 1989, 248, 851.
  • 5-HT 1A 30 ligands may, therefore, be beneficial in the treatment of cardiovascular disorders.
  • agents acting both on the 5-HT-IA receptor including agonists, partial agonists and antagonists, and at the same time blocking the dopamine D 2 receptor are believed to be of potential use in the therapy of such conditions, in particular in the treatment of psychosis, and thus being highly desired.
  • the present invention relates to novel 4-phenylpiperazine, 4-phenylpipe- ridine and 4-phenyl-1 ,2,3,6-tetrahydropyridine compounds of general Formula I:
  • A is a spacer group selected from branched or straight chain C 3 - 8 alkylene, C 3 - 8 alkenylene and C 3 - 8 alkynylene, and C 3 . 7 cycloalkylene, said spacer group being optionally substituted with lower alkyl, aryl or hydroxy;
  • R1 is a branched 0 3 . 10 alkyl, 0 3 . 10 alkenyl or C 3 .
  • R2 - R5 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower alkoxy, lower alkylthio, hydroxy, lower alkylsulfonyl, cyano, lower alkylcarbonyl, phenylcarbonyl, halogen substituted phenylcarbonyl, trifluoromethyl, trifiuoromethylsulfonyloxy, cycloalkyl, cycloalkyl-lower alkyl, nitro, lower alkylamino, di-lower-alkylamino and trifluoromethylthio; R9 and R10 are independently hydrogen, lower alkyl or they may be linked together, thereby forming an ethylene or propylene bridge;
  • V is O, S, CR 6 R 7 , or NR ⁇ wherein R6, R?, and R ⁇ are independently chosen among hydrogen or lower alkyl or lower alkenyl, cycloalkyl, cycloalkyl-lower-alkyl, aryl- lower-alkyl or aryl, or R6 and R? are linked together to constitute a 3-7 membered spirojoined ring;
  • the compounds of the invention have affinity for the 5-HTIA receptor and the dopamin D 2 receptor in vitro and they show 5-HTIA agonistic or antagonistic as well as dopaminergic activity in vivo. Furthermore, the compounds lack cataleptogenic effect or are only weakly cataleptogenic in rats indicating a very low potential for inducing EPS in man. Accordingly, the compounds of the invention are considered useful as drugs for the treatment of psychosis, positive symptoms of schizophrenia, anxiety disorders, such as generalised anxiety disorder, panic disorder, and obsessive compulsive disorder, depression, impulse control disorders, alcohol abuse, aggression, EPS induced by conventional antipsychotic agents, ischaemic disease states, senile dementia and cardiovascular disorders.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising at least one novel 4-phenylpiperazine, 4-phenylpiperidine or 4-phenyl-1 ,2,3,6-tetra- hydropyridine according to the invention as defined above or a pharmaceutically acceptable acid addition salt or prodrug thereof in a therapeutically effective amount and in combination with one or more pharmaceutically acceptable carriers or diluents.
  • the present invention provides the use of a 4-phenylpiperazine, 4-phenylpiperidine or 4-phenyl-1 ,2,3,6-tetrahydropyridine compound according to the invention or an acid addition salt or prodrug thereof for the manufacture of a pharmaceutical preparation for the treatment of the above mentioned disorders and diseases.
  • Prodrugs of the compounds of general Formula I are also embraced by the invention.
  • cycloalkyl designates a carbocyclic ring having 3-8 carbon atoms, inclusive, or a bicyclic or tricyclic carbocycle, such as adamantyl, and cycloalkenyl designate corresponding groups containing an unsaturated bond.
  • lower alkyl refers to branched or unbranched alkyl groups having from one to six carbon atoms inclusive. Examples of such groups are methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2-methyl-2-propyl and 2-methyl-1-propyl.
  • lower alkoxy, lower alkylthio, lower alkylsulfonyl, lower alkylcarbonyl and lower alkyiamino refer to such groups in which the alkyl moiety is a lower alkyl group as defined above, such as methoxy, ethoxy, 1 -propoxy, methylthio, ethylthio, 1- propylthio, 2-propylthio, methylsulfonyl, ethylsulfonyl, etc.
  • lower alkenyl and alkynyl designate such groups having from two to six carbon atoms, inclusive.
  • Preferred lower alkyl, alkenyl and alkynyl groups are those having up to four carbon atoms.
  • aryl refers to a mono- or bicyclic carbocyclic or heterocyclic aromatic group, such as phenyl, indolyl, thienyl, pyrimidyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzofuranyl, benzothienyl, pyridyl, naphthyl, and furanyl, in particular phenyl, pyrimidyl, indolyl, and thienyl.
  • Halogen means fluoro, chloro, bromo or iodo.
  • Acyl refers to an arylcarbonyl, C 1 - 18 alkylcarbonyl, N'-(C -i 8 )alkyl- or N',N'-di(C MS)- alkylcarbonyl group.
  • alk(en/yn)yl means that the group may be an alkyl, alkenyl, or alkynyl group.
  • A is preferably a -(CH 2 ) n - group wherein n is an integer of 3 - 8, inclusive, more preferably 4 - 6, inclusive. Most preferably n is 4.
  • R is preferably branched C 3 - 6 alkyl, cycloalkyl, cycloalkyl-lower alkyl or trifluoro ⁇ methylsulfonyl, more preferably 2-propyl, 2-methyl-1-propyl, 2-butyl, 3-pentyl, 2,2-di- methyl-1 -propyl, tert-butyl, cyclopropylmethyl, cyclopentyl, 2,4-dimethyl-3-pentyl or trifluoromethylsulfonyl, in particular 2-propyl, cyclopentyl, cyclopropylmethyl or trifluo ⁇ romethylsulfonyl.
  • R2-R5 are preferably hydrogen, halogen or cyano and more preferably they are all hydrogen or one of the substituents is halogen and the others are hydrogen.
  • R9 and Rio are preferably both hydrogen.
  • W is preferably oxygen.
  • Preferred compounds are : 3-Cyclohexyl-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 -piperazinyl]butan-1 -y!]-2-imidazo- lidinone.
  • the acid addition salts of the invention are pharmaceutically acceptable salts of the compounds of Formula I formed with non-toxic acids.
  • organic salts are those with maleic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8- bromotheophylline.
  • inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and
  • compositions of this invention or those which are manufactured in accordance with this invention may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenterally in the form of solutions for injection.
  • suitable route for example orally in the form of tablets, capsules, powders, syrups, etc.
  • parenterally in the form of solutions for injection.
  • any pharmaceutically acceptable carriers, diluents, exipients, or other additive usually used in the art may be used.
  • the compounds of the invention are administered in unit dosage form containing said compounds in an amount of about 0.01 to 100 mg.
  • the total daily dose is usually in the range of about 0.05 - 500 mg, and most preferably about 0.1 to 50 mg of the active compound of the invention.
  • the invention moreover relates to a method for the preparation of the novel 4- phenylpiperazines, 4-phenylpiperidines and 4-phenyl-1 ,2,3,6-tetrahydropyridines of Formula I, comprising :
  • R1-R5, R9, Rio, x, v, W, Z, n, and the dotted line are as previously defined and Y is a suitable leaving group such as halogen, mesylate, or tosylate; or
  • R1-R5, R9, Rio, X, v, W, Z, n, and the dotted line are as previously defined;
  • R2-R5, R9, Rio, X, V, W, Z, A and the dotted line are as previously defined with a compound R1Y wherein R1 is as previously defined and Y is a suitable leaving group such as halogen, mesylate, or tosylate; or
  • R1-R5, R9, Rio, x, v, W, Z, A and the dotted line are as previously defined, with and aldehyde R ' CHO, a ketone R “ R '” CO or a carboxylic acid R ' COOH in which formulas R ' , R “ and R '" are groups which together with the nitrogen atom form N-CH 2 R ' and N-CHR " R '" groups, respectively, which are embraced by the previous definition of V; or
  • R1-R5, R9, Rio, X, V, W, Z and A are as previously defined;
  • reaction of a compound of Formula II with a compound of Formula III accor ⁇ ding to Method a) is performed in a suitable organic solvent such as acetone, methyl isobutyl ketone, ethanol, 2-propanol, N-methyl-2-pyrrolidinone, preferably at an elevated temperature, eg. at the boiling point of the solvent, and generally in the presence of a base (such as potassium carbonate or triethylamine).
  • a suitable organic solvent such as acetone, methyl isobutyl ketone, ethanol, 2-propanol, N-methyl-2-pyrrolidinone
  • the reduction according to Method b) is conveniently performed by use of UAIH 4 , AIH 3 or diborane in an inert solvent such as tetrahydrofuran, dioxane, or diethyl ether at room temperature or at a slightly elevated temperature.
  • an inert solvent such as tetrahydrofuran, dioxane, or diethyl ether
  • the reaction of a phenol compound of Formula V according to Method c) is generally performed by initially generating the phenolate ion by addition of a strong base (eg. potassium te/ -butoxide) in an inert solvent such as diethyl ether, tetra ⁇ hydrofuran, toluene, or dimethoxyethane preferably at room temperature or below.
  • a strong base eg. potassium te/ -butoxide
  • an inert solvent such as diethyl ether, tetra ⁇ hydrofuran, toluene, or dimethoxyethane preferably at room temperature or below.
  • the phenolate ion is subsequently reacted with the compound of formula R1Y at an elevated temperature, eg. at the boiling point of the solvent.
  • Trifluoromethylsul- fonyloxy derivatives are conveniently obtained by triflation (see methods in WO 93/11761 Patent publication) of the properly substituted phenols of
  • Triflic acid anhydride, N-phenyltrifluoromethanesulfonimide, and triflic acid chloride are preferred as triflating agents.
  • the reductive alkylation of a compound of Formula VI according to Method d) is generally performed under acidic conditions, eg. in acetic acid, using NaBH 4 , NaCNBH 3 or catalytic (Pt or Pd as catalysts) hydrogenation. Temperatures are generally at room temperature or below.
  • the reduction of a tetrahydropyridinyl double bond of a compound of Formula VII according to Method e) is generally performed by catalytic hydrogenation at low pressure ( ⁇ 3 atm.) ;° a Parr apparatus, or by using a reducing agent such as diborane in an inert solvent such as tetrahydrofuran, dioxane, or diethyl ether.
  • the N-protecting group (carbamate, benzyl, sulfonyl, acetyl) is finally removed in a conventional manner. 5
  • melting points were determined on a B ⁇ chi SMP-20 apparatus and were unadjusted.
  • 1H NMR spectra were recorded at 250 MHz on a Bruker AC 250 spectrometer.
  • Deuterated chloroform (99,8 %D) or dimethylsulfoxide (99,9 %D) were used as solvents.
  • TMS was used as internal reference standard. Chemical shift values are expressed in ppm-values.
  • the 1-(te/f-butyloxycarbonyl) N-protection group was splitted off as in Example 5 yielding 9 g of crude 4-(2-trifluoromethylsulfonyloxyphenyl)piperidine.
  • Example 10 (method c) 3-Cyclohexyl-1 -[4-[4-[2-(1 ,1 -dimethylethoxy)phenyl]-1 -piperidinyl]butan-1 -yl]-2- imidazolidinone oxalate, 10a.
  • the compounds of Formula I have been tested according to well established and reliable pharmacological methods for determination of the activity at the 5-HTIA and the D 2 receptor, repectively, and for cataleptogenic effects. The tests were as described in the following.
  • 5-Methoxy-N,N- dimethyltryptamine is a 5-HTIA agonist.
  • Partiel 5-HTIA agonists such as buspirone inhibit the characteristic 5-HT syndrome produced by 5-MeO DMT.
  • the said test is a test for determining the antagonist effects of a test compound on 5-HTIA receptors in vivo . The test was performed as described in Smith L.M. and Peroutka S.J., Pharmacol. Biochem. Behav., 1986, 24, 1513-1519. The compounds of the present invention were active in this test model.
  • the compounds of the invention show affinity for both 5- HTI A and dopamine D 2 receptors in vivo. Furthermore, they showed 5-HTI A receptor agonistic effect in vivo whereas they did not have cataleptogenic effects. Finally, some of the compounds also showed dopamine D 2 antagonistic effects in vivo. Accordingly, the compounds have a combination of effects at the said two receptors, i.e. acting as agonists, partial agonists or antagonists at the 5-HTI A receptor and blocking the dopamine D 2 receptor without showing cataleptogenic. Drugs having such properties are useful in the treatment the psychic disorders as mentioned previously. They are in particular considered useful in the treatment of psychosis, including positive symptoms of schizophrenia.
  • the pharmaceutical formulations of the invention may be prepared by conventional methods in the art.
  • Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conven ⁇ tional tabletting machine.
  • adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.
  • Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.
  • suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.
  • Typical examples of recipes for the formulation of the invention are as follows: 1 ) Tablets containing 5.0 mg of Compound 4a calculated as the free base:

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a novel series of 4-phenylpiperazines, 4-phenyl-piperidines and 4-phenyl-1,2,3,6-tetrahydropyridines compound of general formula (I) wherein A is alkylene, alkenylene, alkynylene, and C3-7 cycloalkylene; R1 is a C¿3-10? alkyl, alkenyl, or alkynyl group, cycloalk(en)yl, cycloalk(en)yl-alk(en/yn)yl, trifluoromethylsulfonyl, or alkylsulfonyl, R?2 - R5¿ are optional substituents; R?9 and R10¿ are hydrogen, alkyl or together form an ethylene or propylene bridge; W is O or S; V is O, S, CR?6R7, or NR8¿ wherein R?6, R7, and R8¿ are hydrogen or alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, optionally substituted arylalkyl or aryl, or R?6 and R7¿ constitute a 3-7 membered spiroring; Z is -(CH¿2?)m-, m being 2 or 3 or Z is -CH=CH-; X is N, C or CH; show effects on central serotonin 5-HT1A and dopamine D2 receptors. Thus the novel compounds are useful in the treatment of certain psychic and neurologic disorders in particular psychosis.

Description

Serotonin 5-HTIA and dopamin D2 receptor ligands.
Field of Invention
The present invention relates to a novel series of 4-phenylpiperazines, 4-phenyl- piperidines and 4-phenyl-1 ,2,3,6-tetrahydropyridines. Having effects on both central serotonin 5-HT-IA and dopamine D receptors, the novel compounds are useful in the treatment of certain psychic and neurologic disorders.
Background of the Invention
In International patent publication No. WO 92/03426, a class of piperazine deriva¬ tives having phenyl, naphtyl or quinolyl in the 4-position and an N-aryl substituted carbamoyl alkyl group or an N-aryl substituted ureido alkyl group in the 1 -position is described. Said compounds are claimed to exhibit affinity for various receptors, including 5-HT2, 5-HTIA. alpha and dopamine receptors.
EP A1 0376607 relates to certain 1-[4-(3-indolyl)butyl]-4-(2-oxyphenyl)piperazine compounds being partial 5-HT-IA agonists.
EP A1 0526434 among a number of other compounds, describes 1 -[(4-phenyl- piperazin-1 -yl)-C2-6 alkyl]-benzimidazol-2-one compounds said to show 5-HTIA agonistic activity and 5-HT2A antagonistic activity.
US Patent No 3,374,237 discloses a class of 1-phenyl-3-(4-phenyl-1-piperazinyl- C2-4 alkyl)-2-imidazolidinones claimed to be useful as tranquilizers. No test data at all are presented. FR Patents Nos 1.394.708 and 1.513.604, respectively, describe similar compounds without a phenyl substituent in the 4-position of the piperazinyl group and said to possess tranquilizing and psychopharmachodynamic properties, respectively.
AU Patent No 15658/83 discloses 3-(4-phenyl-1-piperazinyl-C2- alkyl)hydantoin compounds having antihypertensive effects. WO 92/00282 relates to a subgroup of the compounds of US Patent No 3,374,237 which are 1-phenyl-3-[4-(4-phenyl-1 -piperazinyl)-1-butyl]-2-imidazolidinones having an optional chloro atom in the 2-position of the phenyl substituent in 1 -position of the imidazolidinone ring and a methoxy or ethoxy substituent in the 2- and/or 3-posi- tion of the other phenyl substituent. The compounds show dopaminergic effects.
Clinical studies of known 5-HTIA partial agonists such as e.g. buspirone, 8-[4-[4-(2- pyrimidyl)-1 -piperazinyl]butyl]-8-azaspiro[4,5]decane-7,9-dione, gepirone, 4,4-dime- thyl-1 -[4-[4-(2-pyrimidyl)-1-piperazinyl]butyl]-2,6-piperidinedione, and ipsapirone, 2- [4-[4-(2-pyrimidyl)-1 -piperazinyl]butyl]-1 ,2-benzothiazol-3(2H)-one-1 , 1 -dioxide, have shown that 5-HT-IA partial agonists are useful in the treatment of anxiety disorders such as generalised anxiety disorder, panic disorder, and obsessive compulsive disorder (Glitz, D. A., Pohl, R., Drugs 1991 , 41, 11). Preclinical studies indicate that also full agonists are useful in the treatment of the above mentioned anxiety related disorders (Schipper , Human Psychopharmacol., 1991 , 6, S53).
There is also evidence, both clinical and preclinical, in support of the beneficial effect of 5-HTTA agonists in the treatment of depression, impulse control disorders and alcohol abuse (van Hest, Psychopharmacol., 1992, 107, 4 '4; Schipper et al, Human Psychopharmacol., 1991 , 6, S53; Cervo et al, Eur. J. Pharmacol., 1988, 158, 53; Glitz, D. A., Pohl, R., Drugs 1991 , 41, 11 ; Grof et al., Int. Clin. Psycho¬ pharmacol. 1993, 8, 167-172; Ansseau et al., Human Psychopharmacol. 1993, 8, 279-283).
5-HT-IA agonists and partial agonists inhibit isolation-induced aggression in male mice indicating that these compounds are useful in the treatment of aggression (Sanchez et al., Psychopharmacology, 1993, 110, 53-59).
Furthermore, 5-HT-IA agonists have been reported to show antipsychotic effect in animal models (Wadenberg and Ahlenius, J. Neural. Transm., 1991 , 83, 43; Ahlenius, Pharmacol.&Toxicol., 1989, 64, 3; Lowe et al., J. Med. Chem., 1991 , 34, 1860; New et al., J. Med. Chem., 1989, 32, 1147;and Martin et al., J. Med. Chem., 1989, 32, 1052) and recent studies also indicate that 5-HT1A receptors are impor¬ tant in the serotonergic modulation of haloperidol-induced catalepsy (Hicks, Life Science 1990, 47, 1609, Wadenberg et al. Pharmacol. Biochem. & Behav. 1994, 47, 509-513) suggesting that 5-HT-|A agonists are useful in the treatment of the 5 extrapyramidal side effects (EPS) induced by conventional antipsychotic agents such as haloperidol.
Damping of dopamine (DA) overactivity by the use of DA receptor blocking drugs is today the most important principle in the treatment of schizophrenia, in particular the ιo positive symptoms thereof, and other psychoses. "Classical neuroleptics" such as haloperidol, cis(Z)-flupentixol and chlorpromazine are believed to induce antipsy¬ chotic effect via DA receptor blockade. Unfortunately, these classical neuroleptics also induce EPS, which seem to be correlated to the propensity of these com¬ pounds to induce catalepsy in rodents (Arnt et al. Neuropharmacology, 1981 , 20,
15 1331-1334). A combination of 5-HT-IA receptor agonism which may prevent EPS in man (cf. above) and dopamine receptor blockade to treat the positive symptoms of schizophrenia would thus be very advantageous.
Furthermore, 5-HT-IA agonists have shown neuroprotective properties in rodent 20 models of focal and global cerebral ischaemia and may, therefore, be useful in the treatment of ischaemic disease states (Prehn , Eur. J. Pharm. 1991 , 203, 213).
Pharmacological studies have been presented which indicate that 5-HT-IA antago¬ nists are useful in the treatment of senile dementia (Bowen et al, Trends Neur. Sci. 25 1992, 15, 84).
Both in animal models and in clinical trials, it has been shown that 5-HT-IA agonists exert antihypertensive effects via a central mechanism (Saxena and Villalόn, Trends Pharm. Sci. 1990, 11, 95; Gillis et al, J. Pharm. Exp. Ther. 1989, 248, 851. 5-HT1A 30 ligands may, therefore, be beneficial in the treatment of cardiovascular disorders.
Accordingly, agents acting both on the 5-HT-IA receptor, including agonists, partial agonists and antagonists, and at the same time blocking the dopamine D2 receptor are believed to be of potential use in the therapy of such conditions, in particular in the treatment of psychosis, and thus being highly desired.
Summary of the Invention
It has now been found that a novel series of phenylpiperazines, 4-phenylpiperidines and 4-phenyl-1 ,2,3,6-tetrahydropyridines posseses both central serotonergic 5-HTIA and antidopaminergic D2 activity.
Accordingly, the present invention relates to novel 4-phenylpiperazine, 4-phenylpipe- ridine and 4-phenyl-1 ,2,3,6-tetrahydropyridine compounds of general Formula I:
Figure imgf000006_0001
wherein A is a spacer group selected from branched or straight chain C3-8 alkylene, C3-8 alkenylene and C3-8 alkynylene, and C3.7 cycloalkylene, said spacer group being optionally substituted with lower alkyl, aryl or hydroxy; R1 is a branched 03.10 alkyl, 03.10 alkenyl or C3.10 alkynyl group, cycloalk(en)yl, cycloalk(en)yl-lower alk(en/yn)yl, trifluoromethylsulfonyl, or lower alkylsulfonyl, R2 - R5 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower alkoxy, lower alkylthio, hydroxy, lower alkylsulfonyl, cyano, lower alkylcarbonyl, phenylcarbonyl, halogen substituted phenylcarbonyl, trifluoromethyl, trifiuoromethylsulfonyloxy, cycloalkyl, cycloalkyl-lower alkyl, nitro, lower alkylamino, di-lower-alkylamino and trifluoromethylthio; R9 and R10 are independently hydrogen, lower alkyl or they may be linked together, thereby forming an ethylene or propylene bridge; W is O or S;
V is O, S, CR6R7, or NRβ wherein R6, R?, and Rβ are independently chosen among hydrogen or lower alkyl or lower alkenyl, cycloalkyl, cycloalkyl-lower-alkyl, aryl- lower-alkyl or aryl, or R6 and R? are linked together to constitute a 3-7 membered spirojoined ring;
Z is -(CH2)m-. m being 2 or 3 or Z is -CH=CH-; the dotted line, emanating from X, indicates an optional bond and when it does not indicate a bond X is N or CH and when it indicates a bond X is C; any alkyl, cycloalkyl or cycloalkylalkyl group present being optionally substituted with one or two hydroxy groups, which again are optionally esterified with an ali¬ phatic or aromatic carboxylic acid; and any aryl substituent present being optionally substituted with halogen, lower alkyl, lower alkoxy, lower alkylthio, hydroxy, lower alkylsulfonyl, cyano, acyl, trifluoromethyl, trifluoromethylsulfonyloxy, cycloalkyl, cyclo¬ alkylalkyl or nitro; and pharmaceutically acceptable acid addition salts thereof.
The compounds of the invention have affinity for the 5-HTIA receptor and the dopamin D2 receptor in vitro and they show 5-HTIA agonistic or antagonistic as well as dopaminergic activity in vivo. Furthermore, the compounds lack cataleptogenic effect or are only weakly cataleptogenic in rats indicating a very low potential for inducing EPS in man. Accordingly, the compounds of the invention are considered useful as drugs for the treatment of psychosis, positive symptoms of schizophrenia, anxiety disorders, such as generalised anxiety disorder, panic disorder, and obsessive compulsive disorder, depression, impulse control disorders, alcohol abuse, aggression, EPS induced by conventional antipsychotic agents, ischaemic disease states, senile dementia and cardiovascular disorders.
In another aspect, the invention provides a pharmaceutical composition comprising at least one novel 4-phenylpiperazine, 4-phenylpiperidine or 4-phenyl-1 ,2,3,6-tetra- hydropyridine according to the invention as defined above or a pharmaceutically acceptable acid addition salt or prodrug thereof in a therapeutically effective amount and in combination with one or more pharmaceutically acceptable carriers or diluents.
In a further aspect, the present invention provides the use of a 4-phenylpiperazine, 4-phenylpiperidine or 4-phenyl-1 ,2,3,6-tetrahydropyridine compound according to the invention or an acid addition salt or prodrug thereof for the manufacture of a pharmaceutical preparation for the treatment of the above mentioned disorders and diseases.
Detailed Description of the Invention
Some of the compounds of general Formula I may exist as optical isomers thereof and such optical isomers are also embraced by the invention.
Prodrugs of the compounds of general Formula I are also embraced by the invention.
The term cycloalkyl designates a carbocyclic ring having 3-8 carbon atoms, inclusive, or a bicyclic or tricyclic carbocycle, such as adamantyl, and cycloalkenyl designate corresponding groups containing an unsaturated bond.
The term lower alkyl refers to branched or unbranched alkyl groups having from one to six carbon atoms inclusive. Examples of such groups are methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2-methyl-2-propyl and 2-methyl-1-propyl. Accordingly, the terms lower alkoxy, lower alkylthio, lower alkylsulfonyl, lower alkylcarbonyl and lower alkyiamino refer to such groups in which the alkyl moiety is a lower alkyl group as defined above, such as methoxy, ethoxy, 1 -propoxy, methylthio, ethylthio, 1- propylthio, 2-propylthio, methylsulfonyl, ethylsulfonyl, etc. Similarly, lower alkenyl and alkynyl, respectively, designate such groups having from two to six carbon atoms, inclusive. Preferred lower alkyl, alkenyl and alkynyl groups are those having up to four carbon atoms.
The term aryl refers to a mono- or bicyclic carbocyclic or heterocyclic aromatic group, such as phenyl, indolyl, thienyl, pyrimidyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzofuranyl, benzothienyl, pyridyl, naphthyl, and furanyl, in particular phenyl, pyrimidyl, indolyl, and thienyl.
Halogen means fluoro, chloro, bromo or iodo. Acyl refers to an arylcarbonyl, C1-18 alkylcarbonyl, N'-(C -i8)alkyl- or N',N'-di(C MS)- alkylcarbonyl group.
The expression alk(en/yn)yl means that the group may be an alkyl, alkenyl, or alkynyl group.
In Formula I, A is preferably a -(CH2)n- group wherein n is an integer of 3 - 8, inclusive, more preferably 4 - 6, inclusive. Most preferably n is 4.
R is preferably branched C3-6 alkyl, cycloalkyl, cycloalkyl-lower alkyl or trifluoro¬ methylsulfonyl, more preferably 2-propyl, 2-methyl-1-propyl, 2-butyl, 3-pentyl, 2,2-di- methyl-1 -propyl, tert-butyl, cyclopropylmethyl, cyclopentyl, 2,4-dimethyl-3-pentyl or trifluoromethylsulfonyl, in particular 2-propyl, cyclopentyl, cyclopropylmethyl or trifluo¬ romethylsulfonyl.
R2-R5 are preferably hydrogen, halogen or cyano and more preferably they are all hydrogen or one of the substituents is halogen and the others are hydrogen. R9 and Rio are preferably both hydrogen.
Z is preferably -CH2CH2- or -CH=CH- and V preferably designates N-Rβ, wherein R8 is lower alkyl, cycloalkyl, phenyl or phenyl substituted with halogen, most preferably cyclohexyl, adamantyl, isopropyl or 4-fluorophenyl. W is preferably oxygen.
Preferred compounds are : 3-Cyclohexyl-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 -piperazinyl]butan-1 -y!]-2-imidazo- lidinone.
3-(4-Fluorophenyl)-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 -piperazinyl]butan-1 -yl]-2-imida- zolidinone.
3-Cyclohexyl-1 -[4-[4-(2-cyclopentyloxyphenyl)-1-piperazinyl]butan-1 -yl]-2-imidazo- lidinone.
1 -[4-[4-(2-Cyclopentyloxyhenyl)-1 -piperazinyl]butan-1 -yl]-3-(4-f luorophenyl)-2-imida- zolidinone.
1 -[3-[4-[2-(2-Propyloxy)phenyl]-1 -piperazinyl]-1 -propyl]-3-phenyl-2-imidazolidinone. 3-(4-Fluoropheny!)-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]butan-1 -yl]-2- imidazolidinone.
3-Cyclohexyl-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]butan-1 -yI]-2-imidazolidi- none. 3-Cyclohexyi-1 -[3-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]-1 -propyl]-2-imida- zolidinone.
3-(2-Propyl)-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]-1 -butyl]-2-imidazolidinone.
3-Cyclohexyl-1 -[6-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]hexan-1-yl]-2-imidazo- lidinone. 3-Cyclohexyl-1 -[4-[4-(2-cyclopropylmethyloxyphenyl)-1 -piperidinyl]butan-1 -yl]-2- imidazolidinone.
3-Cyclohexyl-1 -[4-[4-[2-(2,2-dimethylpropyloxy)phenyl]-1 -piperidinyl]butan-1 -yl]-2- imidazolidinone.
3-Cyclohexyl-1-[4-[4-[2-(2-propyloxy)phenyl]-1-piperidinyl]butan-1-yl]-1 ,3-dihydroimi- dazol-2-one.
3-(1-Adamantyl)-1-[4-[4-[2-(2-propyloxy)phenyl]-1-piperidinyl]butan-1-yl]-1 ,3-dihydro- imidazol-2-one.
3-(4-Fluorophenyl)-1-[4-[4-[2-(2-trifluoromethylsuIfonyloxy)phenyl]-1 -piperazinyl]- butan-1 -yl]-2-imidazolidinone. 3-Cyclohexyl-1 -[4-[4-[2-(2-trifluoromethylsulfonyloxy)phenyl]-1 -piperazinyl]butan-1- yl]-2-imidazolidinone.
3-(4-Fluorophenyl)-1 -[4-[4-[2-(2-trifluoromethylsulfonyloxy)phenyl]-1 -piperidinyl]- butan-1 -yl]-2-imidazolidinone.
3-Cyclohexyl-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 ,2,3,6-tetrahydropyridin-1 -yl]butan-1 - yl]-2-imidazolidinone.
3-(4-Fluorophenyl)-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 ,2,3, 6-tetrahyd ropy ridin-1 - yl]butan-1-yl]-2-imidazolidinone.
3-Cyclohexyl-1 -[4-[4-[2-(cyclopropylmethoxy)phenyl]-1 ,2,3,6-tetrahydropyridin-1 - yl]butan-1-yl]-2-imidazolidinone. 3-Cyclohexyl-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 ,2,3,6-tetrahydropyridin-1 -yl]butan-1 - yl]-2,3-dihydroimidazol-2-one.
3-(1 -Adamantyl)-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 ,2,3,6-tetrahydropyridin-1 -yl]butan-
1-yl]-2,3-dihydroimidazol-2-one. 3-Cyclohexyl-1 -[4-[4-[2-( 1 , 1 -dimethylethyl) oxy)phenyl]-1 -p iperidinyl]butan-1 -yl]-2- imidazolidinone.
3-Cyclohexyl-1 -[4-[4-[2-cyclopropyloxyphenyl]-1 -p iperidinyl]butan-1 -y l]-2-i mida- zolidinone. 3-Cyclopentyl-1 -[3-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]butan-1 -yl]-2-imidazo- lidinone.
3-Cyclohexyl-1 -[4-[4-[5-fluoro-2-(2-propyloxy)phenyl]-1 -piperidinyl]butan-1 -yl]-2- imidazolidinone.
3-Cyclohexyl-1 -[4-[4-[4-chloro-2-(2-propyloxy)phenyl]-1 -piperidinyl]butan-1 -yl]-2- imidazolidinone.
3-Cyclohexyl-1 -[4-[4-[5-bromo-2-(2-propyloxy)phenyl]-1 -piperidinyl]butan-1 -yl]-2- imidazolidinone.
3-Cyclohexyl-1 -[4-[4-[5-cyano-2-(2-propyloxy)phenyl]-1 -piperidinyl]butan-1 -yl]-2- imidazolidinone. 3-Adamantyi-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]butan-1 -yI]-2 -imidazo¬ lidinone.
3-Cyclohexyl-1-[4-[4-[2-(2,4-dimethyl-3-pentyloxy)phenyl]-1 -piperidinyl]butan-1-yl]-2- imidazolidinone.
The acid addition salts of the invention are pharmaceutically acceptable salts of the compounds of Formula I formed with non-toxic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8- bromotheophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids.
The pharmaceutical compositions of this invention or those which are manufactured in accordance with this invention may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenterally in the form of solutions for injection. For preparing such compositions methods well known in the art may be used, and any pharmaceutically acceptable carriers, diluents, exipients, or other additive usually used in the art may be used.
Conveniently, the compounds of the invention are administered in unit dosage form containing said compounds in an amount of about 0.01 to 100 mg.
The total daily dose is usually in the range of about 0.05 - 500 mg, and most preferably about 0.1 to 50 mg of the active compound of the invention.
The invention moreover relates to a method for the preparation of the novel 4- phenylpiperazines, 4-phenylpiperidines and 4-phenyl-1 ,2,3,6-tetrahydropyridines of Formula I, comprising :
a) reacting a compound of Formula II with a compound of Formula III :
Figure imgf000012_0001
wherein R1-R5, R9, Rio, x, v, W, Z, n, and the dotted line are as previously defined and Y is a suitable leaving group such as halogen, mesylate, or tosylate; or
b) reducing the amide carbonyl of a compound of Formula IV :
Figure imgf000012_0002
wherein R1-R5, R9, Rio, X, v, W, Z, n, and the dotted line are as previously defined; or
c) reacting a compound of Formula V :
Figure imgf000013_0001
wherein R2-R5, R9, Rio, X, V, W, Z, A and the dotted line are as previously defined with a compound R1Y wherein R1 is as previously defined and Y is a suitable leaving group such as halogen, mesylate, or tosylate; or
d) reductive alkylation of the NH group of a compound of the Formula VI :
Figure imgf000013_0002
wherein R1-R5, R9, Rio, x, v, W, Z, A and the dotted line are as previously defined, with and aldehyde R'CHO, a ketone R"R'"CO or a carboxylic acid R'COOH in which formulas R', R" and R'" are groups which together with the nitrogen atom form N-CH2R' and N-CHR"R'" groups, respectively, which are embraced by the previous definition of V; or
e) reducing the double bond of the 1 ,2,3,-6-tetrahydropyridine derivative of Formula VII : 12
Figure imgf000014_0001
wherein R1-R5, R9, Rio, X, V, W, Z and A are as previously defined;
whereupon the compound of Formula I is isolated as the free base or a pharmaceu¬ tically acceptable acid addition salt thereof.
The reaction of a compound of Formula II with a compound of Formula III accor¬ ding to Method a) is performed in a suitable organic solvent such as acetone, methyl isobutyl ketone, ethanol, 2-propanol, N-methyl-2-pyrrolidinone, preferably at an elevated temperature, eg. at the boiling point of the solvent, and generally in the presence of a base (such as potassium carbonate or triethylamine).
The reduction according to Method b) is conveniently performed by use of UAIH4, AIH3 or diborane in an inert solvent such as tetrahydrofuran, dioxane, or diethyl ether at room temperature or at a slightly elevated temperature.
The reaction of a phenol compound of Formula V according to Method c) is generally performed by initially generating the phenolate ion by addition of a strong base (eg. potassium te/ -butoxide) in an inert solvent such as diethyl ether, tetra¬ hydrofuran, toluene, or dimethoxyethane preferably at room temperature or below. The phenolate ion is subsequently reacted with the compound of formula R1Y at an elevated temperature, eg. at the boiling point of the solvent. Trifluoromethylsul- fonyloxy derivatives are conveniently obtained by triflation (see methods in WO 93/11761 Patent publication) of the properly substituted phenols of Formula V. Triflic acid anhydride, N-phenyltrifluoromethanesulfonimide, and triflic acid chloride are preferred as triflating agents. The reductive alkylation of a compound of Formula VI according to Method d) is generally performed under acidic conditions, eg. in acetic acid, using NaBH4, NaCNBH3 or catalytic (Pt or Pd as catalysts) hydrogenation. Temperatures are generally at room temperature or below.
5
The reduction of a tetrahydropyridinyl double bond of a compound of Formula VII according to Method e) is generally performed by catalytic hydrogenation at low pressure (< 3 atm.) ;° a Parr apparatus, or by using a reducing agent such as diborane in an inert solvent such as tetrahydrofuran, dioxane, or diethyl ether.
10
The 1-Unsubstituted 4-arylpiperazines of Formula II (X = N) are either commercially available or may be synthesized from the corresponding anilines and N',N'-bis(2- chloroethyl)amine by refluxing in highboiling solvents as eg. chlorobenzene typically for some days (2-3) according to methods described in Martin et al. J. Med. Chem. 15 1989, 32 1052-1056.
The 4-Phenylpiperidines of Formula II (X = CH) are either commercially available or prepared as described in eg. US Pat. No. 2,891 ,066; McElvain et al. J.Amer.Chem. Soc 1950, 72, 3134; Bally et al Chem.Ber. 1887, 20, 2590. The corresponding 4- 0 phenyl-1 ,2,3,6-tetrahydropyridines of Formula II (X = C) are prepared from N- protected 4-piperidones by addition of properly substituted phenyl lithium or phenyl magnesium halides followed by acid catalyzed water elimination. The N-protecting group (carbamate, benzyl, sulfonyl, acetyl) is finally removed in a conventional manner. 5
The synthesis of more specific compounds of Formula II are given in detail in the Experimental Section.
1-(3-Chloropropyl)-, 1-(4-chlorobutyl)-, 1-(5-chloropentyl)-, and 1-(6-chlorohexyl)-2- 0 imidazolidinones or the corresponding 3-substituted 2-imidazolidinones were prepared according to methods in Perregaard et al. J.Med.Chem. 1992, 35, 1092- 1101 or references cited therein, or the detailed methods are described below. Experimental Section
In the following, the invention is further illustrated by examples which, however, may not be construed as limiting.
In all examples, melting points were determined on a Bϋchi SMP-20 apparatus and were unadjusted. 1H NMR spectra were recorded at 250 MHz on a Bruker AC 250 spectrometer. Deuterated chloroform (99,8 %D) or dimethylsulfoxide (99,9 %D) were used as solvents. TMS was used as internal reference standard. Chemical shift values are expressed in ppm-values. The following abbreviations are used for multiplicity of NMR signals : s=singlet, d=doublet, t=triplet, q=quartet, p=pentet, h=heptet, dd=double doublet, dt=double triplet, dq=double quartet, qui=quintet of triplets, m=multiplet.
Example 1 (analogous to method d)
1 -(4-Chloro-1 -butyl)-3-cyclohexyl-2-imidazolidinone 1 a
A mixture of 1-(4-chloro-1-butyl)-2-imidazolidinone (50 g) and cyclohexanone (83.3 g) in glacial acetic acid (1000 ml) was stirred for one hour at room temperature. The mixture was cooled to 10-15 °C and NaBH 4 (42.4 g) was added in small portions during 5 hours. After stirring overnight at room temperature, acetic acid was evaporated in vacuo. Water (500 ml) and dichloromethane (300 ml) were added and pH adjusted to >9 by addition of aqueous diluted NH4OH. The organic phase was separated, dried with anhydrous MgS04, filtered and the solvent evaporated in vacuo. The remaining crude product was purified by column chromatography on silica gel (eluted with ethyl acetate). The pure title compound 1 a crystalized upon standing. Yield : 33 g, mp : 30-35 °C.
In a corresponding manner the following imidazolidinones were prepared :
1 -(3-Chloro-1 -propyl)-3-cyclohexyl-2-imidazolidinone 1 b. 1 -(4-Chloro-1 -butyl)-3-isopropyl-2-imidazolidinone, 1 c. 1 -(6-Chloro-1 -hexyl)-3-cyclohexyl-2-imidazolidinone, 1 d. Example 2
1 -(4-Chloro-1 -butyl)-3-(4-fluorophenyl)-2-imidazolidinone 2a
To 2-aminoethanol (1100 g) in ethanol (1000 ml) was added 4-chlorobutanol (220 g). The mixture was refluxed for 4 hours. After cooling to 10 °C, sodium methoxide in methanol (380 ml) was added. The precipitate was filtered off and volatile material was evaporated in vacuo. The remaining oil was distilled at reduced pressure. 4-[N-(2-hydroxyethyl)amino]butanol was collected at 135-140 °C at 0.2- 0.4 mmHg. Yield : 106 g. The aminoalcohol (25 g) was dissolved in dichloro¬ methane (150 ml) and a solution og 4-fluorophenylisocyanate (26 g) in dichloro¬ methane (25 ml) was added dropwise at 0-8 °C. After reflux for 2 hours the solvent was evaporated in vacuo leaving the crude 1-(2-hydroxyethyl)-1-(4-hydroxybutyl)-3- (4-fluorophenyl)urea as an oil. Yield : 56 g. To a solution of all of the crude urea derivative and N,N-dimethylformamide (DMF, 1 ml) in dichloromethane (250 ml) was added dropwise a solution of thionylchloride (40 ml) in dichloromethane (60 ml) at 10-20 °C. The mixture was refluxed for 3 hours. Volatile material was evaporated in vacuo. This remaining material was heated at 130-150 °C for 2 hours. Dichloro¬ methane (50 ml) was added and the mixture was directly filtered through silica gel (eluted with a 1 :1 mixture of ethyl acetate and heptane). The title compound 2a crystallized upon evaporation of the solvents. Yield : 33 g, mp : 62-64 °C.
In a corresponding manner the following imidazolidinone was prepared :
1 -(3-Chloro-1-propyl)-3-phenyl-2-imidazolidinone 2b.
Example 3.
4-(3-Cyclohexyl-1 ,3-dihydroimidazol-2-on-1-yl)-1 -butyl methanesulfonate, 3a.
A mixture of 4-butyrolactone (54 g) and aminoacetaldehyde dimethylacetal (55 g) in tetrahydrofuran (THF) (500 ml_) was refluxed for 4 h. A further portion of amino¬ acetaldehyde dimethylacetal (27 g) was added followed by reflux for 2 h. Reflux was continued and two further portions of acetal were added at 2 h intervals. Concentra- tion of the reaction mixture in vacuo followed by destination of the remaining oil gave N-(2,2-dimethoxyethyl)-4-hydroxybutyramide as an oil, bp. 230 °C/10 torr, yield 72 g. The oil was dissolved in dry THF (800 mL) and added slowly to a suspension of of lithium aluminium hydride in THF (200 mL). After reflux for 16 h, the reaction mixture was cooled and subsequently quenched with water (88 mL), 15% NaOH solution (44 mL), and water (220 mL). Filtration and removal of solvent in vacuo gave an oil which was dissolved in methylene chloride (500 mL) and dried over magnesium sulfate. Filtration and removal of solvent in vacuo gave 4-(2,2-dimetho- xyethylamino)-1-butanol as an oil, yield 62 g. A portion of the oil (20 g) was dissol- ved in methylene chloride (100 mL) and added dropwise to a solution of cyclo- hexylisocyanate in methylene chloride (50 mL) at 5 °C. Reflux for 3 h and concentra¬ tion in vacuo gave N-cyclohexyl-N'-(2,2-dimethoxyethyl)-N'-(4-hydroxy-1-butyl)urea as an oil, yield 35 g. The oil was dissolved in a mixture of THF (200 mL) and 2 M hydrochloric acid (200 mL) followed by reflux for 24 h. The reaction mixture was concentrated in vacuo followed by addition of ethyl acetate (300 mL) and 4 M NaOH (300 mL). The organic phase was dried over magnesium sulfate. Removal of solvent gave 1-cyclohexyl-3-(4-hydroxy-1-butyl)-1 ,3-dihydroimidazol-2-one as an oil, yield 29 g. The oil was dissolved in methylene chloride (250 mL) and triethylamine (13 g) was added followed by cooling to 5 °C. A solution of methanesulfonyl chloride (14 g) in methylene chloride (20 mL) was added dropwise followed by stirring for 1.5 h at room temperature. The reaction mixture was washed with water, dried over magnesium sulfate and concentrated in vacuo giving the title compound as an oil, yield 36 g. 1H NMR (CDCI3): δ 1.05-1.25 (m, 1 H), 1.30-1.50 (m, 4H), 1.60-2.00 (m, 9H), 3.00 (s, 3H), 3.65 (t, 2H), 3.85-4.05 (m, 1 H), 4.25 (t, 2H), 6.20 (d, 1 H), 6.25 (d, 1 H).
In a corresponding manner the following 1 ,3-dihydroimidazol-2-one was prepared :
4-[3-(1 -Adamantyl)-1 ,3-dihydroimidazol-2-on-1 -yl]-1 -butyl methanesulfonate, 3b.
Example 4 (method a)
3-Cyclohexyl-1-[4-[4-[2-(2-propyloxy)phenyl]-1 -piperazinyI]butan-1 -yl]-2-imidazolidi- none, oxalate 4a. A mixture of 1-[2-(2-propyloxy)phenyl]piperazine (5.0 g), 1 -(4-chloro-1 -butyl)-3- cyclohexyi -imidazoIidinone 1a (3.0 g), a crystal of potassium iodide, and potas¬ sium carbonate (4.0 g) in methyl isobutyl ketone (MIBK) (100 ml) was refluxed for 16 hours. Inorganic salts were filtered off while still hot. After cooling to room temperature, the crude reaction mixture was filtered through silica gel (eluted with a 1 :1 mixture of ethyl acetate and methanol). After evaporation of the solvents 3.9 g of crude product was left as a visceous oil. The oxalate salt crystallized from acetone. Yield: 2.4 g, mp : 133-134 °C. 1 H NMR (DMSO-d6) δ 1.00-1.80 (m,14H); 1.25 (h,6H); 2.85-3.30 (m,16H); 3.35-3.55 (m,1 H); 4.60 (h,1 H); 6.80-7.00 (m,4H).
In a similar way the following compounds were prepared :
3-(4-Fluorophenyl)-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 -piperazinyl]butan-1 -yl]-2- imidazolidinone 4b, mp: 135-137 °C (ethyl acetate). 1H NMR (CDCI 3) δ 1.45 (d, 6H); 1.60 (t, 4H); 2.45 (t, 2H); 2.65 (broad s, 4H); 3.15 (broad s, 4H); 3.35 (t, 2H); 3.50 (t, 2H); 3.80 (t, 2H); 4.60 (h, 1H); 6.85-7.00 (m, 4H); 7.05 (t, 2H); 7.50 (dd, 2H).
3-Cyclohexyl-1 -[4-[4-(2-cyclopentyloxyphenyl)-1 -piperazinyl]butan-1 -yl]-2-imidazolidi- none, dihydrochloride 4c, mp: 182-193 °C (acetone). 1H NMR (DMSO-d6) δ 1.05- 2.00 (m, 22H); 3.05-3.20 (m, 8H); 3.40-3.55 (m, 5H); 4.85 (qui, 1 H); 6.85-7.00 (m, 4H); 7.60 (broad s, 1 H); 11.05 (broad s, 1 H).
1 -[4-[4-(2-Cyclopentyloxyphenyl)-1 -piperazinyl]butan-1 -yl]-3-(4-fluorophenyl)-2- imidazolidinone, 4d, mp: 111 -116 °C (acetone). 1 H NMR (CDCI3) δ 1.60-1.95 (m,12H); 2.40 (broad t, 2H); 2.65 (broad s, 4H); 3.05 (broad s, 4H); 3.25 (broad t, 2H); 3.45 (t, 2H); 3.75 (t, 2H); 4.80 (qui, 1 H); 6.80-7.05 (m, 6H); 7.45 (dd, 2H).
1 -[3-[4-(2-(2-propyloxy)phenyl)-1 -piperazinyl]-1 -propyl]-3-phenyl-2-imidazolidinone, 4e, mp: 167-68 °C (ethanol). 1H NMR (CDCI3) δ 1.25 (d, 6H), 1.75 (qui, 2H), 2.60 (t, 2H), 2.75 (m, 4H), 3.05 (m, 4H), 3.25 (t, 2H), 3.45 (t, 2H), 3.80 (t, 2H), 4.60 (h, 1H), 6.60 (s, 3H), 6.80-6.95 (m, 4H), 7.00 (t, 1 H), 7.30 (t, 2H), 7.55 (d, 2H). Example 5
1 -(terf-Butyloxycarbonyl)-4-(2-hydroxyphenyl)piperidine 5a
2-Methoxybenzaldehyde (200 g) and ethyl acetoacetate (400 g) were mixed and 5 cooled to 5 °C. Piperidine (25 ml) was added and the mixture was stirred overnight at room temperature. The next day potassium te/τ-butoxide (25 g) was added. After 1.5 hours the mixture totally solidified and was left for 2 days. Ethanol (2000 ml) was added and the pricipitate was filtered off, washed with ethanol and finally dried in vacuo. Yield : 326 g. All of the thus obtained solid product (325 g) was added in ιo small portions during one hour to a solution of potassium hydroxide (260 g) in water (320 ml) kept at 80-90 °C. After stirring for further two hours at 80 °, water (2000 ml) and diethyl ether (1000 ml) were added. After stirring, the organic phase was separated and discarded. To the remaining aqueous solution was added ice and concentrated hydrochloric acid until pH < 1. After stirring for 45 minutes, the
15 precipitated product was filtered off and dried. Yield of 3-(2-methoxyphenyl)-1 ,5- pentanedicarboxylic acid : 137 g, mp : 183-185 °C. A mixture of the pentane- dicarboxylic acid (97 g) and urea (28 g) was heated at 160-165 °C for 2 hours. After cooling to 70 °C, ethanol (150 ml) was added. The precipitated 4-(2- methoxyphenyl)-2,6-piperidinedione was filtered off and subsequently dried. Yield :
20 66 g. Mp : 127-129 °C. To a suspension of LiAIH4 (30 g) in dry THF (1000 ml) were added small portions (in total 65 g) of the piperidinedione while the temperature gradually raised to reflux. After reflux for 2.5 hours, the mixture was cooled below 10 °C and diluted aqueous NaOH solution (4M) (60 ml) was cautiously added. Precipita¬ ted inorganic salts were filtered off. The solvent was evaporated and the remaining
25 oil was dissolved in dichloromethane, dried (anh. Na2S04), filtered and dichlorome¬ thane evaporated leaving 56 g of 4-(2-methoxyphenyl)piperidine as an oil. All of the piperidine was dissolved in a mixture of 48% aqueous hydrobromic acid (400 ml) and a 33% solution of hydrogenbromide in acetic acid (400 ml). The solution was refluxed for 19 hours. Excess hydrobromic and acetic acids was evaporated in
30 vacuo leaving 47 g of 4-(2-hydroxyphenyl)piperidine hydrobromide as a visceous oil. The hydrobromide (45 g) was dissolved in a mixture of water (300 ml) and THF (150 ml). Potassium carbonate (80 g) was added in small lots. A solution of d\-tert- butyldicarbonate (40 g) in THF (150 ml) was added dropwise. The mixture was stirred overnight. The aqueous phase was separated and washed with dietyl ether (2 x 100 mi). The combined organic phases were dried (anh. MgSθ4) and the solvents evaporated. The remaining product was stirred with diisopropyl ether and the precipitated product was filtered off. Yield of the title phenol derivative 5a : 24 g, mp : 187-189 °C.
Example 6 (method a)
3-(4-Fluorophenyl)-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]butan-1 -yl]-2- imidazolidinone, oxalate 6a.
To a solution of 1-(fe/7-Butyloxycarbonyl)-4-(2-hydroxyphenyl)piperidine 5a (5 g) in dry THF (100 ml) was added potassium tert-butoxide (2.2 g). After stirring for 5 minutes 2-iodopropane (9 g) was added and the mixture was refluxed for 3 hours. Additionally 1.1 g of potassium te/ -butoxide was added and reflux was continued overnight. After cooling to room temperature inorganic salts were filtered off and the solvents evaporated in vacuo. The remaining oil was purified by filtering through silica gel (eluted with a 7:3 mixture of heptane and ethyl acetate). Yield : 4.5 g of 1- (te/τ-butyloxycarbonyl)-4-[2-(2-propyloxy)phenyl]piperidine all of which was dissol¬ ved in a mixture of dichloromethane (90 ml) and trifluoroacetic acid (40 ml). After stirring for one hour at room temperature all volatile material was evaporated in vacuo. To the remaining oil was added ethyl acetate (200 ml) and water (200 ml). pH was adjusted to >10 by addition of diluted aqueous NH4OH. The organic phase was separated and washed with brine (2 x 50 ml). Work-up of the organic phase as above yielded 2.6 g of 4-[2-(2-propyloxy)phenyl]piperidine. A mixture of the thus isolated 1-unsubstituted piperidine (2.5 g), 1-(4-chloro-1-butyl)-3-(4-fluorophenyl)-2- imidazolidinone 2a (3.0 g), potassium carbonate (1.6 g), and potassium iodide (0.5 g) in MIBK (50 ml) was refluxed overnight. Inorganic salts were filtered off and MIBK evaporated in vacuo. The remaining crude product was purified by column chroma¬ tography on silica gel (eluted with 4% triethylamine in ethyl acetate). Pure title compound 6a crystallized from ethyl acetate. Yield : 2.6 g, mp : 130-131 °C. 1H NMR (CDCI3) δ 1.45 (d, 6H); 1.60 (t, 4H); 1.70-1.90 (m, 4H); 2.00-2.15 (m, 2H); 2.40 (t, 2H); 2.90-3.05 (m, 3H); 3.35 (t, 2H); 3.45 (t, 2H); 3.75 (t, 2H); 4.55 (h, 1 H); 6.80-6.90 (m, 2H); 7.00 (t, 2H); 7.10 (dt, 1 H); 7.15 (dd, 1 H); 7.50 (dd, 2H). In a similar way the following compounds were prepared :
3-Cyclohexyl-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]butan-1 -yl]-2-i mida- zolidinone, oxalate, 6b, mp: 138-141 °C (acetone). 1H NMR (DMSO-cfe): δ 0.95-1.20 (m, 1 H), 1.20-1.40 (m, 4H), 1.30 (d, 6H), 1.40-1.80 (m, 9 H), 1.80-2.00 (m, 4H), 2.90-3.20 (m, 7H), 3.25 (s, 4H), 3.40-3.60 (m, 3H), 4.65 (h, 1 H), 6.90 (t, 1 H), 7.00 (d, 1 H), 7.10-7.25 (m, 2H).
3-Cyclohexyl-1 -[3-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]-1 -propyl]-2-imida- zolidinone, oxalate, 6c, mp: 136-39 °C (acetone). 1H NMR (DMSO- 6): δ 0.95-1.45 (m, 5H), 1.30 (d, 6H), 1.50-1.65 (m, 3H), 1.65-2.00 (m, 8H), 2.85-3.15 (m, 7H), 3.25 (s, 4H), 3.40-3.60 (m, 3H), 4.60 (h, 1 H), 6.90 (t, 1 H), 7.00 (d, 1 H), 7.05-7.25 (m, 2H).
3-(2-Propyl)-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]-1 -butyl]-2-imidazolidinone, oxalate, 6d, mp: 82-4 °C (acetone). 1H NMR (DMSO- cfe): δ 1.05 (d, 6H), 1.25 (d, 6H), 1.40-1.55 (m, 2H), 1.55-1.75 (m, 2H), 1.80-2.00 (m, 4H), 2.90-3.15 (m, 7H), 3.15-3.30 (m, 4H), 3.40-3.60 (m, 2H), 3.90 (h, 1 H), 4.60 (h, 1 H), 6.90 (t, 1 H), 7.00 (d, 1 H), 7.05-7.25 (m, 2H).
3-Cyclohexyl-1 -[6-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]-1 -hexyl]-2-imidazolidino- ne, oxalate, 6e, mp: 77-9 °C (acetone). 1H NMR (DMSO-d6): δ 0.95-1.50 (m, 14H), 1.25 (d, 6H), 1.50-1.80 (m, 6H), 1.80-2.00 (m, 4H), 2.80-3.15j (m, 7H), 3.15-3.25 (m, 4H), 3.35-3.60 (m, 3H), 4.60 (h, 1 H), 6.90 (t, 1 H), 7.00 (d, 1 H), 7.05-7.25 (m, 2H).
3-Cyclohexyl-1 -[4-[4-[2-(cyclopropylmethoxy)phenyl]-1 -piperidinyl]butan-1 -y l]-2- imidazolidinone, oxalate, 6f, mp: 186-93 °C (ethyl acetate). 1H NMR (DMSO- 6): δ 0.25-0.40 (m, 2H), 0.60-0.70 (m, 2H), 0.95-1.15 (m, 1 H), 1.20-1.45 (m, 5H), 1.50- 1.90 (m, 9H), 1.95-2.10 (m, 2H), 2.10-2.35 (m, 2H), 2.85 (t, 2H), 3.05-3.25 (m, 3H), 3.20 (t, 2H), 3.25-3.35 (m, 4H), 3.55-3.85 (m, 3H), 3.80 (d, 2H), 6.80 (d, 1H), 6.90 (t, 1), 7.10-7.25 (m, 2H). 3-Cyclohexyl-1-[4-[4-[2-(2,2-dimethyl-1-propyloxy)phenyl]-1-piperidinyl]butan-1-yl]-2- imidazolidinone oxalate, 6g, mp: 162-68 °C (ethyl acetate/acetone). 1H NMR (DM- SO-cfe): δ 1.05 (s, 9H), 1.15-1.85 (m, 14H), 1.80-2.05 (m, 4H), 2.85-3.15 (m, 7H), 3.20 (s, 4H), 3.35-3.60 (m, 3H), 3.65 (s, 2H), 6.85-7.00 (m, 2H), 7.05-7.25 (m, 2H).
By an analogous method, but applying mesylates 3a and 3b instead of chlorides as alkylating reagents the following derivatives were prepared:
3-Cyclohexyl-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 -piperidinyl]butan-1 -yl]-1 ,3-dihydro- imidazol-2-one, oxalate, 6h, mp: 68-71 °C (acetone). 1H NMR (DMSO- cfe): δ 1.05- 1.55 (m, 5H), 1.30 (d, 6H), 1.55-1.85 (m, 9H), 1.85-2.00 (m, 4H), 2.90-3.20 (m, 5H), 3.40-3.60 (m, 4H), 3.75 (dt, 1 H), 4.65 (h, 1 H), 6.50 (d, 1 H), 6.55 (d, 1 H), 6.90 (t, 1 H), 7.00 (d, 1 H), 7.10-7.25 (m, 2H).
3-(1-Adamantyl)-1-[4-[4-[2-(2-propyloxy)phenyl]-1-piperidinyl]butan-1-yl]-1 ,3-dihydro- imidazol-2-one, oxalate, 6i, mp: 116-22 °C (ethyl acetate/acetone). 1 H NMR (DMSO-de): δ 1.30 (d, 6H), 1.50-1.75 (m, 10H), 1.75-2.10 (m, 4H), 2.00-2.20 (m, 9H), 2.85-3.20 (m, 5H), 3.35-3.60 (m, 4H), 4.65 (h, 1 H), 6.50 (s, 2H), 6.90 (t, 1 H), 7.00 (d, 1 H), 7.05-7.25 (m, 2H).
Example 7 (method a)
3-(4-Fluorophenyl)-1-[4-[4-[2-(2-trifluoromethylsulfonyloxy)phenyl]-1 -piperidinyl]- butan-1 -yl]-2-imidazolidinone 7a.
A solution of 1 -(ferf-butyloxycarbonyl)-4-(2-hydroxyphenyl)piperidine 5a (9 g) and triethylamine (7 ml) in dichloromethane (90 ml) was cooled to 5 °C and a solution of trifluoromethansulfonic acid anhydride (10 ml) in dichloromethane (15 ml) was added dropwise. After stirring for one hour at room temperature water (200 ml) was added. The organic phase was separated and worked-up as previously. Yield of crude 1-(tø/ -butyloxycarbonyl)-4-(2-trifluoromethylsulfonyloxyphenyl)piperidine : 14 g. The 1-(te/f-butyloxycarbonyl) N-protection group was splitted off as in Example 5 yielding 9 g of crude 4-(2-trifluoromethylsulfonyloxyphenyl)piperidine. A mixture of the thus isolated 1-unsubstituted piperidine (5.5 g), 1 -(4-chloro-1-butyl)-3-(4- fluorophenyl)-2-imidazolidinone 2a (4.0 g), and potassium iodide (0.5 g) in MIBK (80 ml) was refluxed overnight. MIBK was evaporated in vacuo. The remaining oil was dissolved in ethyl acetate (100 ml) and water (100 ml) and pH was adjusted to >9 by addition of diluted aqueous NH4OH. The organic phase was separated and worked- up as previously. The remaining crude product was purified by column chromato¬ graphy on silica gel (eluted with 4% triethylamine in a 9:1 mixture of ethyl acetate and ethanol). Pure title compound 7a crystallized from a 1 :1 mixture of diethyl and diisopropyl ether. Yield : 2.0 g, mp: 77-79 °C. 1H NMR (CDCI 3) δ 1. 55-1.70 (m, 4H); 1.70-1.85 (m, 4H); 2.05 (dt, 2H); 2.40 (t, 2H); 2.80-2.95 (m, 1 H); 3.05 (d, 2H); 3.35 (t, 2H); 3.45 (t, 2H); 3.80 (t, 2H); 7.00 (t, 2H); 7.20-7.45 (m, 4H); 7.50 (dd, 2H).
In a similar way the following trifluoromethylsulfonyloxy derivatives were prepared:
3-Cyclohexyl-1 -[4-[4-[2-(2-trif luoromethylsulfonyloxy) phenyl]-1 -piperazinyl]butan-1 - yrj-2-imidazolidinone, hydrochloride 7b, mp: 153-154 °C (acetone). 1 H NMR
(DMSO-d6) δ 1.00-1.75 (m, 14H); 3.00-3.55 (m, 17H); 7.25-7.50 (m, 4H); 11.20 (s,
1 H).
3-(4-Fluorophenyl)-1-[4-[4-[2-(2-trifluoromethylsulfonyloxy)phenyl]-1 -piperazinyl]- butan-1 -yl]-2-imidazolidinone, 7c, mp: 68-70 °C (diisopropyl ether). 1H NMR (CDCI3) δ 1. 55-1.65 (m, 4H); 2.45-2.55 (m, 2H); 2.65 (broad s, 4H); 3.05 (t, 4H); 3.35 (t, 2H);
3.50 (t, 2H); 3.80 (t, 2H); 7.00-7.20 (m, 5H); 7.35 (dt, 1 H); 7.50 (dd, 2H).
Example 8
4-[2-(2-propyloxy)phenyl]-1 ,2,3,6-tetrahydropyridine 8a.
2-Bromophenol (10 g), 2-bromopropane (7.1 g), potassium carbonate (12 g), and a potassium iodide crystal were refluxed in MIBK (100 ml) for 6 hours. Inorganic salts were filtered off and MIBK evaporated in vacuo. Ice cooled water and diethyl ether (200 ml) were added and pH adjusted to >10 by adding diluted aqueous NaOH. The organic phase was separated and worked-up as above. Yield of 2-bromophenyl 2- propyl ether (11 g) as an oil. To diethyl ether (38 ml) cooled below -10 °C was added a 1.6 M solution of n-butyl lithium in hexane (31 ml). The resulting solution was cooled to -50 °C and all off the 2-bromophenyl 2-propyl ether from above in diethyl ether (20 ml) was added dropwise. After stirring for another 20 minutes at- 50 °C a solution of 1 -benzyl-4-piperidone (9.7 g) in diethyl ether (25 ml) was added dropwise at -50 °C. The mixture was allowed gradually to heat to -10 °C and poured into diluted aqueous hydrochloric acid. The organic phase was discarded and diluted aqueous NH4OH was added until pH>9. Extraction with diethyl ether (2 x 200 ml) and work-up of the organic phase as above yielded the 1-benzyl-4-hydroxy- 4-[2-(2-propyloxy)phenyl]piperidine (13.7 g) as an oil. All of the hydroxypiperidine was refluxed in trifluoroacetic acid (100 ml) for 2.5 hours. Ice (1000 g) and diethyl ether (300 ml) were added and pH was adjusted to > 9 by addition of diluted aqueous NH4OH. After extraction several times (3 x 200 ml) with diethyl ether, the combined organic phases were worked-up as previously. The crude product was purified by column chromatography on silica gel (eluted with 4% triethylamine in a 3:1 mixture of heptane and ethyl acetate). Yield : 4.2 g as an oil. To all of the thus obtained 1 -benzyl-4-[2-(2-propyloxy)phenyl]-1 ,2,3,6-tetrahydropyridine in 1 ,1 ,1 - trichloroethane (40 ml) was added dropwise a solution of 2,2,2-trichloroethyl chloroformate (2,2 ml) in trichloroethane (10 ml) at reflux temperature. After reflux for 1.5 hours the solvent was evaporated. The crude product was filtered through silica gel (eluted with ethyl acetate / heptane 1 :3) affording 4.5 g of the pure 2,2,2- trichloroethyl carbamate derivative as an oil. All of this carbamate was dissolved in acetic acid (40 ml). Water was added and at 40-50 °C Zn powder (8 g) was added in small portions during 10 minutes. After stirring for 2 hours at 50 °C inorganic salts were filtered off and the solvents were evaporated in vacuo. Ice and ethyl acetate were added and pH adjusted to >9 by addition of diluted aqueous NH4OH. The organic phase was separated and worked-up as above yielding 2.5 g of the title compound 8a as an oil.
Example 9
3-Cyclohexyl-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 ,2,3,6-tetrahydropyridin-1 -yl]butan-1 - yl]-2-imidazolidinone oxalate 9a.
A mixture of 4-[2-(2-propyloxy)phenyl]-1 ,2,3,6-tetrahydropyridine 8a (2.3 g), 1-(4- chloro-1 -butyl)-3-cyclohexyl-2-imidazolidinone 1 a (1.25 g), potassium carbonate (1.6 g) and a potassium iodide crystal in MIBK (60 ml) was refluxed overnight. Inorganic salts were filtered off and the solvent was evaporated in vacuo. The crude title compound 9a was purified by column chromatography on silica gel (eluted with 4% triethylamine in a 3:1 mixture of ethyl acetate and heptane). Yield : 1 g as an oil. The oxalate salt crystallized from 2-propanol, mp: 131-133 °C.
In a similar way the following tetrahydropyridinyl derivatives were prepared :
3-(4-Fluorophenyl)-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 ,2,3,6-tetrahydropyridin-1 - yl]butan-1-yl]-2-imidazolidinone oxalate 9b, mp 150-2 °C (acetone). 1 H NMR (DMSO-of6): δ 1.25 (d, 6H), 1.45-1.65 (m, 2H), 1.65-1.80 (m, 2H), 2.60-2.80 (m, 2H), 3.10 (t, 2H), 3.20 (t, 2H), 3.20-3.35 (m, 2H), 3.45 (t, 2H), 3.65-3.90 (m, 4H), 4.60 (h, 1 H), 5.65-5.80 (m, 1 H), 6.90 (t, 1 H), 7.00 (d, 1 H), 7.05-7.20 (m, 3H), 7.25 (t, 1 H), 7.50-7.65 (m, 2H).
3-Cyclohexyl-1 -[4-[4-[2-(cyclopropylmethoxy)phenyl]-1 ,2,3,6-tetrahydropyridin-1 - yl]butan-1-yl]-2-imidazolidinone 9c, colorless oil. 1H NMR (CDCI3): δ 0.25-0.45 (m, 2H), 0.50-0.75 (m, 2H), 0.90-1.00 (m, 1 H), 1.00-1.95 (m, 14H), 2.50 (t, 2H), 2.55- 2.75 (m, 4H), 3.05-3.15 (m, 2H), 3.20 (t, 2H), 3.25 (s, 4H), 3.30 (dt, 1 H), 3.80 (d, 2H), 5.75-5.80 (m, 1 H), 6.80 (d, 1 H), 6.90 (t, 1 H), 7.10-7.30 (m, 2H).
By an analogous method, but applying mesylates 3a and 3b instead of chlorides as alkylating reagents the following derivatives were prepared:
3-Cyclohexyl-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 ,2,3,6-tetrahydropyridin-1 -yl]butan-1 - yl]-2,3-dihydroimidazol-2-one 9d, colorless oil. 1 H NMR (CDCI3): δ 1.10-1.50 (m, 5H), 1.30 (d, 6H), 1.50-1.75 (m, 5H), 1.75-2.00 (m, 4H), 2.45 (t, 2H), 2.50-2.60 (m, 2H), 2.60-2.68 (m, 2H), 3.05-3.15 (m, 2H), 3.65 (t, 2H), 3.90-4.05 (m, 1 H), 4.50 (h, 1 H), 5.70-5.75 (m, 1 H), 6.20 (d, 1 H), 6.25 (d, 1 H), 6.90 (t, 2H), 7.10-7.25 (m, 2H).
3-(1 -Adamantyl)-1 -[4-[4-[2-(2-propyloxy)phenyl]-1 ,2,3,6-tetrahydropyridin-1 -yljbutan- 1-yl]-2,3-dihydroimidazol-2-one oxalate 9e, mp: 104-9 °C (ethyl acetate/acetone). 1H NMR (DMSO-d6): δ 1.25 (d, 6H), 1.50-1.75 (m, 10H), 2.00-2.20 (m, 9H), 2.60- 2.80 (m, 2H), 3.00-3.20 (m, 2H), 3.30 (t, 2H), 3.50 (t, 2H), 3.70-3.85 (m, 2H), 4.60 (h, 1 H), 5.70-5.80 (m, 1 H), 6.50 (s, 2H), 6.90 (t, 1 H), 7.00 (d, 1 H), 7.15 (d, 1 H), 7.25 (t, 1 H).
Example 10 (method c) 3-Cyclohexyl-1 -[4-[4-[2-(1 ,1 -dimethylethoxy)phenyl]-1 -piperidinyl]butan-1 -yl]-2- imidazolidinone oxalate, 10a.
A solution of 3-cyclohexyl-1 -[4-[4-(2-hydroxyphenyl)-1 -piperidinyl]butan-1-yl]-2- imidazolidinone (1 g, prepared from 4-(2-hydroxyphenyl)piperidine (described in Example 5) and 1 a by the method described in Example 4) in dry methylene chloride (10 ml) was cooled to -20 °C. Isobutylene (5 ml, condensed at -25 °C) was added under a nitrogen atmosphere followed by addition of trifluoromethanesulfonic acid (0.4 ml). The mixture was stirred for 3 h at -20 °C followed by addition of triethylamine (2 mL). After warming to room temperature the reaction mixture was concentrated in vacuo followed by addition of 2 M ammonia and extraction with methylene chloride. The organic phase was dried over magnesium sulfate and concentrated in vacuo leaving an oil which was purified by flash chromatography (silica gel, eluent: ethyl acetate/MeOH/triethylamine 97:2:1). The resulting colorless oil was dissolved in a mixture of ethyl acetate and acetone. Addition of oxalic acid gave the title compound, 10a, as a crystalline material. Yield: 0.8 g, mp: 147-53 °C. 1H NMF DMSO-cfe): δ 0.95-2.10 (m, 18H), 1.35 (s, 9H), 2.85-3.15 (m, 7H), 3.25 (s, 4H), 3.35-3.60 (m, 3H), 6.90-7.25 (m, 4H).
Pharmacology
The compounds of Formula I have been tested according to well established and reliable pharmacological methods for determination of the activity at the 5-HTIA and the D2 receptor, repectively, and for cataleptogenic effects. The tests were as described in the following.
Inhibition of 3H-8-OH-DPAT Binding to Serotonin 5-HTiA Receptors in Rat Brain in vitro.
By this method the inhibition by drugs of the binding of the 5-HTιA agonist 3H-8- OH-DPAT (1 nM) to 5-HTIA receptors in membranes from rat brain minus cerebel¬ lum is determined in vitro . Accordingly, this is a test for affinity for the 5-HTIA receptor. The test was performed as described by Hyttel et al., Drug Dev. Res. 1988, 75, 389-404.
Inhibition of 3H-spiroperidol Binding to Dopamine D2 Receptors in Rat Brain in vitro.
By this method the inhibition by drugs of the binding of the D2 antagonist 3H- spiroperidol (0.5 nM) to D2 receptors in membranes from rat corpus striatum is determined in vitro . Accordingly, this is a test for affinity for the dopamine D2 receptor. This method is described in detail in J. Hyttel et al, J. Neurochem., 1985, 44, 1615. The results of the binding assays are given in Table 1.
Table 1 Binding Data (IC50 values in nM)
Compound No 3H 8-OH DPAT (5-HT1A) 3H Spiroperidole (D2)
_
4a 1.8 4 4bb 2 2..22 3.9
4c 5.4 13.
4d 4.0 15.
4e 40. 24.
6a 4.8 7.9 6 6bb 5 5..44 8.7.
6c 35. 1 10.
6d 5. 7.7
6e 20. 16.
6f 26. 37. 6 6hh 4 4..11 10.
7a 37. 41.
7b 42. 49.
7c 15. 57.
9a 9. 8.7 9 9bb 2 2..88 1 1 .
9d 26. 27.
buspirone 41. 250. haloperidol 3200. 7.5 Cataleptogenic effect.
Evaluation of cataleptogenic effects of the compounds of the invention was made according to the method of Sanchez, C. et al.; Drug Dev. Res. 19gi , 22 , 239-250. Examples of compounds tested are shown in Table 2
Table 2 (ED50 values in μmol/kg)
Compound No Catalepsy (1-6 h, sc)
4a >38
4b >44
4c >37
4d >42.
4e >34
6a >44
6b >38
6d >41
6e >33
6h >38
7b >35
7c >37
9a >38
9b >37 haloperidol 0.36
Furthermore, the compounds of the present invention were tested with respect to their ability to inhibit 5-MeO-DMT-induced 5-HT syndrome in rats. 5-Methoxy-N,N- dimethyltryptamine (5-MeO DMT) is a 5-HTIA agonist. Partiel 5-HTIA agonists such as buspirone inhibit the characteristic 5-HT syndrome produced by 5-MeO DMT. Accordingly the said test is a test for determining the antagonist effects of a test compound on 5-HTIA receptors in vivo . The test was performed as described in Smith L.M. and Peroutka S.J., Pharmacol. Biochem. Behav., 1986, 24, 1513-1519. The compounds of the present invention were active in this test model.
The compounds were also tested in the Methylphenidate test as published by Pedersen and Christensen in Acta Pharmacol, et Toxicol. 31 , 488-496 (1972) and in the Pergolide Rotation Test as published by Arnt, J. and Hyttel, J., J. Neural. Transm. 1986, 67, 225-240. Both these testmodels are in vivo tests for antidopami- nergic activity. Some of the compounds of the invention also showed effects in these test models.
As seen from the above, the compounds of the invention show affinity for both 5- HTI A and dopamine D2 receptors in vivo. Furthermore, they showed 5-HTI A receptor agonistic effect in vivo whereas they did not have cataleptogenic effects. Finally, some of the compounds also showed dopamine D2 antagonistic effects in vivo. Accordingly, the compounds have a combination of effects at the said two receptors, i.e. acting as agonists, partial agonists or antagonists at the 5-HTI A receptor and blocking the dopamine D2 receptor without showing cataleptogenic. Drugs having such properties are useful in the treatment the psychic disorders as mentioned previously. They are in particular considered useful in the treatment of psychosis, including positive symptoms of schizophrenia.
Formulation Examples
The pharmaceutical formulations of the invention may be prepared by conventional methods in the art.
For example: Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conven¬ tional tabletting machine. Examples of adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.
Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc. Typical examples of recipes for the formulation of the invention are as follows: 1 ) Tablets containing 5.0 mg of Compound 4a calculated as the free base:
Compound 4a 5.0 mg
Lactose 60. mg
Maize starch 30. mg
Hydroxypropylcellulose 2.4 mg
Microcrystalline cellulose 19.2 mg
Croscarmellose Sodium Type A 2.4 mg
Magnesium stearate 0.84 mg
2) Tablets containing 0.5 mg of Compound 4a calculated as the free base:
Compound 4a 0.5 mg
Lactose 46.9 mg
Maize starch 23.5 mg
Povidone 1.8 mg
Microcrystalline cellulose 14.4 mg
Croscarmellose Sodium Type A 1.8 mg
Magnesium stearate 0.63 mg
3) Syrup containing per millilitre:
Compound 4b 25 mg
Sorbitol 500 mg
Hydroxypropylcellulose 15 mg
Glycerol 50 mg
Methyl-paraben 1 mg
Propyl-paraben 0.1 mg
Ethanol 0.005 ml
FlavourO.05 mg
Saccharin natrium 0.5 mg
Water ad 1 ml
4) Solution for injection containing per millilitre:
Compound 6b 0.5 mg Sorbitol 5.1 mg Acetic acid 0.08 mg Water for injection ad 1 ml

Claims

1. A 4-phenylpiperazine, 4-phenylpiperidine and 4-phenyl-1 ,2,3,6-tetrahydropyri- dine compound of general Formula I:
Figure imgf000033_0001
wherein A is a spacer group selected from branched or straight chain C3-8 alkylene, C3-8 alkenylene and C3.8 alkynylene, and C3.7 cycloalkylene, said spacer group being optionally substituted with lower alkyl, aryl or hydroxy; R1 is a branched C3-10 alkyl, 03- 0 alkenyl or C3.10 alkynyl group, cycloalk(en)yl, cycloalk(en)yl-lower alk(en/yn)yl, trifluoromethylsulfonyl, or lower alkylsulfonyl, R2 - R5 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower alkoxy, lower alkylthio, hydroxy, lower alkylsulfonyl, cyano, lower alkylcarbonyl, phenylcarbonyl, halogen substituted phenylcarbonyl, trifluoromethyl, trifluoromethylsulfonyloxy, cycloalkyl, cycloalkyl-lower alkyl, nitro, lower alkylamino, di-lower-alkylamino and trifluoromethylthio; R9 and R o are independently hydrogen, lower alkyl or they may be linked together, thereby forming an ethylene or propylene bridge; W is O or S;
V is O, S, CR6R7, or NRβ wherein R6, R?, and Rβare independently chosen among hydrogen or lower alkyl or lower alkenyl, cycloalkyl, cycloalkyl-lower-alkyl, aryl- lower-alkyl or aryl, or R6 and R? are linked together to constitute a 3-7 membered spirojoined ring;
Z is -(CH2)m-, m being 2 or 3 or Z is -CH=CH-; the dotted line, emanating from X, indicates an optional bond and when it does not indicate a bond X is N or CH and when it indicates a bond X is C; any alkyl, cycloalkyl or cycloalkylalkyl group present being optionally substituted with one or two hydroxy groups, which again are optionally esterified with an ali¬ phatic or aromatic carboxylic acid; and any aryl substituent present being optionally substituted with halogen, lower alkyl, lower alkoxy, lower alkylthio, hydroxy, lower alkylsulfonyl, cyano, acyl, trifluoromethyl, trifluoromethylsulfonyloxy, cycloalkyl, cyclo- alkylalkyl or nitro; or a pharmaceutically acceptable acid addition salt thereof.
2. A compound of Claim 1 , characterized in that A is a -(CH2)n- group wherein n is an integer of 3 - 8, inclusive.
3. A compound of Claim 2, characterized in that n is 4 - 6, preferably 4.
4. A compound of any of Claims 1 - 3, characterized in that R is branched C3-6 alkyl, cycloalkyl, cycloalkyl-lower alkyl or trifluoromethylsulfonyl.
5. A compound of Claim 4, characterized in that R1 is 2-propyl, 2-methyl-1- propyl, 2-butyl, 3-pentyl, 2,2-dimethyl-1-propyl, tert-butyl, cyclopentyl, cyclopropyl¬ methyl, 2,4-dimethyl-3-pentyl or trifluoromethylsulfonyl.
6. A compound of any of Claims 1 - 5, characterized in that R2-R5 are hydrogen, halogen or cyano.
7. A compound of Claim 5, characterized in that R2-R5 are all hydrogen or one of R2-R5 is halogen and the others are hydrogen.
8. A compound of any of Claims 1 - 7, characterized in that R9 and R1° are both hydrogen.
9. A compound of any of Claims 1 - 8, characterized in that Z is -CH2CH2- or -CH=CH- and V designates N-R 8, wherein R°> is lower alkyl, cycloalkyl, phenyl or phenyl substituted with halogen.
10. A compound of any of Claims 1 - 9, characterized in that W is oxygen.
11. A pharmaceutical composition characterized in that it comprises at least one compound of of any of Claims 1-10 in a therapeutically effective amount and in combination with one or more pharmaceutically acceptable carriers or diluents.
12. Use of a compound of of any of Claims 1-10 or a pharmaceutically acceptable acid addition salt or prodrug thereof for the manufacture of a pharmaceutical preparation for the treatment of psychosis, positive symptoms of schizophrenia, anxiety disorders, such as generalised anxiety disorder, panic disorder, and obsessive compulsive disorder, depression, impulse control disorders, alcohol abuse, aggression, EPS induced by conventional antipsychotic agents, ischaemic disease states, senile dementia and cardiovascular disorders.
PCT/DK1995/000229 1994-06-08 1995-06-08 Serotonin 5-ht1a and dopamin d2 receptor ligands WO1995033729A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
NZ288180A NZ288180A (en) 1994-06-08 1995-06-08 4-phenyl-(piperazine, piperidine or tetrahydropyridine) derivatives
AU27322/95A AU686400B2 (en) 1994-06-08 1995-06-08 Serotonin 5-HT-1A and dopamin D-2 receptor ligands
EP95922420A EP0770066B1 (en) 1994-06-08 1995-06-08 Serotonin 5-ht 1a and dopamin d2 receptor ligands
RU97100172A RU2140920C1 (en) 1994-06-08 1995-06-08 Compound of 4-phenylpiperazine, 4-phenylpiperidine and 4-phenyl- -1,2,3,6-tetrahydropyridine and pharmaceutical composition eliciting 5-ht1a- and d2-activity
PL95317530A PL180847B1 (en) 1994-06-08 1995-06-08 Ligands of serotonin receptors 5-htia and dopamine receptors d2
DE69517027T DE69517027T2 (en) 1994-06-08 1995-06-08 SEROTONIN 5-HT 1A AND DOPAMINE D2 RECEPTOR LIGANDS
JP8500193A JPH10500959A (en) 1994-06-08 1995-06-08 Serotonin 5-HT (lower 1A) and dopamine D (lower 2) receptor ligand
DK95922420T DK0770066T3 (en) 1994-06-08 1995-06-08 Serotin 5-HT 1A and dopamine D2 receptor ligands
BR9507930A BR9507930A (en) 1994-06-08 1995-06-08 4-phenylpyrazine compound 4-phenylpiperadine and 4-phenyl-1,2,3,6, -tetrahydropyridine pharmaceutical composition and use of a compound
SI9530429T SI0770066T1 (en) 1994-06-08 1995-06-08 Serotonin 5-ht 1a and dopamin d2 receptor ligands
SK1549-96A SK281646B6 (en) 1994-06-08 1995-06-08 4-phenylpiperazines, 4-phenyl-piperidines and 4-phenyl-1,2,3,6- -tetrahydropyridines, pharmaceutical means containing them and their use
AT95922420T ATE193016T1 (en) 1994-06-08 1995-06-08 SEROTONIN 5-HT 1A AND DOPAMINE D2 RECEPTOR LIGANDS
NO965183A NO308534B1 (en) 1994-06-08 1996-12-04 Serotonin 5-HT1A and dopamine D2 receptor ligands
FI964897A FI964897A0 (en) 1994-06-08 1996-12-05 Serotonin 5HT1A and dopamine D2 receptor ligands
US09/424,930 US6514993B1 (en) 1994-06-08 1996-12-09 Serotonin 5-HT1A and dopamin D2 receptor ligands
HK97102506A HK1000877A1 (en) 1994-06-08 1997-12-18 Serotonin 5-ht1a and dopamin d2 receptor ligands
GR20000401802T GR3034105T3 (en) 1994-06-08 2000-08-02 Serotonin 5-ht 1a and dopamin d2 receptor ligands
US10/334,481 US20030120070A1 (en) 1994-06-08 2002-12-30 Serotonin 5-HT1A and dopamin D2 receptor ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK65794 1994-06-08
DK0657/94 1994-06-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/424,930 Continuation US6514993B1 (en) 1994-06-08 1996-12-09 Serotonin 5-HT1A and dopamin D2 receptor ligands

Publications (1)

Publication Number Publication Date
WO1995033729A1 true WO1995033729A1 (en) 1995-12-14

Family

ID=8096051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1995/000229 WO1995033729A1 (en) 1994-06-08 1995-06-08 Serotonin 5-ht1a and dopamin d2 receptor ligands

Country Status (27)

Country Link
US (2) US6514993B1 (en)
EP (1) EP0770066B1 (en)
JP (1) JPH10500959A (en)
KR (1) KR100382812B1 (en)
CN (1) CN1067057C (en)
AT (1) ATE193016T1 (en)
AU (1) AU686400B2 (en)
BR (1) BR9507930A (en)
CA (1) CA2192113A1 (en)
CZ (1) CZ287801B6 (en)
DE (1) DE69517027T2 (en)
DK (1) DK0770066T3 (en)
ES (1) ES2148527T3 (en)
FI (1) FI964897A0 (en)
GR (1) GR3034105T3 (en)
HK (1) HK1000877A1 (en)
HU (1) HUT76470A (en)
IL (1) IL114027A (en)
MX (1) MX9605863A (en)
NO (1) NO308534B1 (en)
NZ (1) NZ288180A (en)
PL (1) PL180847B1 (en)
PT (1) PT770066E (en)
RU (1) RU2140920C1 (en)
SK (1) SK281646B6 (en)
WO (1) WO1995033729A1 (en)
ZA (1) ZA954688B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065887A1 (en) * 1998-06-15 1999-12-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6159990A (en) * 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
EP1072601A2 (en) * 1999-05-28 2001-01-31 Pfizer Inc. 4-arylpiperidine derivatives for the treatment of pruritus
EP1113014A1 (en) * 1999-12-30 2001-07-04 Adir Et Compagnie Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them
WO2002039988A2 (en) * 2000-11-14 2002-05-23 Merck Patent Gmbh Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists
WO2003074518A1 (en) * 2002-03-06 2003-09-12 Merck Patent Gmbh Thiazole derivatives and their use d2- and 5-ht1a-receptor ligands
US7049330B2 (en) 1998-06-15 2006-05-23 Wyeth Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US7872030B2 (en) 2001-07-26 2011-01-18 Merck Patent Gmbh Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
US7928128B2 (en) 2000-03-10 2011-04-19 Merck Patent Gesellschaft Mit Beschrankter Haftung Use of(R)-(−) -2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
US8455652B2 (en) 2003-04-03 2013-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitors for the soluble epoxide hydrolase
US8476043B2 (en) 2004-10-20 2013-07-02 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US8501777B2 (en) 2005-10-13 2013-08-06 Nsab, Filial Af Neurosearch Sweden Ab, Sverige 3,5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission
US8513302B2 (en) 2003-04-03 2013-08-20 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CN110143947A (en) * 2019-05-29 2019-08-20 华东师范大学 A kind of preparation method of Ceritinib analog
US11207308B2 (en) 2012-04-04 2021-12-28 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253576A1 (en) * 2003-04-04 2004-12-16 The Regents Of The University Of California Modulating cooperative activity of dopamine D1 and D2 receptors to mitigate substance abuse
EP1817032A2 (en) * 2004-11-29 2007-08-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786308B2 (en) * 2005-03-28 2010-08-31 Vertex Pharmaceuticals Incorporated Muscarinic modulators
US8422893B2 (en) 2010-01-21 2013-04-16 Samsung Electronics Co., Ltd Developer and image forming apparatus including the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374237A (en) * 1965-05-21 1968-03-19 American Cyanamid Co 1-phenyl-3-(4-phenyl-1-piperazinoalkyl)-imidazolidinones and imidazolidinethiones
GB1456253A (en) * 1972-12-23 1976-11-24 Boehringer Sohn Ingelheim Piperazine derivatives
US4452798A (en) * 1982-06-22 1984-06-05 Warner-Lambert Company 1-Substituted phenyl-4-alkyl hydantoin piperazine compounds as antihypertensive agents
WO1992000282A1 (en) * 1990-06-29 1992-01-09 The Upjohn Company Substituted 1-(alkoxyphenyl)piperazines with cns and antihypertensive activity
WO1993003016A1 (en) * 1991-07-30 1993-02-18 Boehringer Ingelheim Italia S.P.A. Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists
WO1994006768A1 (en) * 1992-09-11 1994-03-31 Mcneilab, Inc. Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207310B (en) * 1988-12-02 1993-03-29 Pfizer Process for producing aryl-piperidine derivatives
US5698573A (en) * 1993-09-15 1997-12-16 Merck, Sharp & Dohme, Ltd. Imidazolone and oxazolone derivatives as dopamine antagonists
US6150367A (en) * 1997-10-20 2000-11-21 Council Of Scientific & Industrial Research 1-[4-arylpiperazin-1-yl]-3-[2-oxopyrrolidin/piperidin-1-yl]propanes and their use in medical treatments

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374237A (en) * 1965-05-21 1968-03-19 American Cyanamid Co 1-phenyl-3-(4-phenyl-1-piperazinoalkyl)-imidazolidinones and imidazolidinethiones
GB1456253A (en) * 1972-12-23 1976-11-24 Boehringer Sohn Ingelheim Piperazine derivatives
US4452798A (en) * 1982-06-22 1984-06-05 Warner-Lambert Company 1-Substituted phenyl-4-alkyl hydantoin piperazine compounds as antihypertensive agents
WO1992000282A1 (en) * 1990-06-29 1992-01-09 The Upjohn Company Substituted 1-(alkoxyphenyl)piperazines with cns and antihypertensive activity
WO1993003016A1 (en) * 1991-07-30 1993-02-18 Boehringer Ingelheim Italia S.P.A. Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists
WO1994006768A1 (en) * 1992-09-11 1994-03-31 Mcneilab, Inc. Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620815B1 (en) 1997-06-18 2003-09-16 Synaptic Pharmaceutical Corporation Oxazolidinones and uses thereof
US6159990A (en) * 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
WO1999065887A1 (en) * 1998-06-15 1999-12-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US7049330B2 (en) 1998-06-15 2006-05-23 Wyeth Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
EP1072601A2 (en) * 1999-05-28 2001-01-31 Pfizer Inc. 4-arylpiperidine derivatives for the treatment of pruritus
EP1072601A3 (en) * 1999-05-28 2001-02-14 Pfizer Inc. 4-arylpiperidine derivatives for the treatment of pruritus
US6750231B2 (en) 1999-05-28 2004-06-15 Pfizer Inc 4-arylpiperidine derivatives for the treatment of pruritus
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
FR2803298A1 (en) * 1999-12-30 2001-07-06 Adir NOVEL LINEAR OR CYCLIC UREAS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP1113014A1 (en) * 1999-12-30 2001-07-04 Adir Et Compagnie Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them
US7928128B2 (en) 2000-03-10 2011-04-19 Merck Patent Gesellschaft Mit Beschrankter Haftung Use of(R)-(−) -2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
WO2002039988A3 (en) * 2000-11-14 2002-07-25 Merck Patent Gmbh Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists
WO2002039988A2 (en) * 2000-11-14 2002-05-23 Merck Patent Gmbh Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists
US7872030B2 (en) 2001-07-26 2011-01-18 Merck Patent Gmbh Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
WO2003074518A1 (en) * 2002-03-06 2003-09-12 Merck Patent Gmbh Thiazole derivatives and their use d2- and 5-ht1a-receptor ligands
US8455652B2 (en) 2003-04-03 2013-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitors for the soluble epoxide hydrolase
US8513302B2 (en) 2003-04-03 2013-08-20 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US8476043B2 (en) 2004-10-20 2013-07-02 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US8501777B2 (en) 2005-10-13 2013-08-06 Nsab, Filial Af Neurosearch Sweden Ab, Sverige 3,5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission
US11207308B2 (en) 2012-04-04 2021-12-28 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
CN110143947A (en) * 2019-05-29 2019-08-20 华东师范大学 A kind of preparation method of Ceritinib analog
CN110143947B (en) * 2019-05-29 2021-10-15 华东师范大学 Preparation method of ceritinib analogue

Also Published As

Publication number Publication date
IL114027A0 (en) 1995-10-31
CZ358996A3 (en) 1997-05-14
KR100382812B1 (en) 2003-08-21
EP0770066A1 (en) 1997-05-02
NO965183L (en) 1996-12-04
CN1154107A (en) 1997-07-09
JPH10500959A (en) 1998-01-27
DE69517027T2 (en) 2000-12-21
FI964897A (en) 1996-12-05
PL317530A1 (en) 1997-04-14
IL114027A (en) 1999-11-30
ES2148527T3 (en) 2000-10-16
DK0770066T3 (en) 2000-10-09
GR3034105T3 (en) 2000-11-30
AU686400B2 (en) 1998-02-05
ATE193016T1 (en) 2000-06-15
DE69517027D1 (en) 2000-06-21
CZ287801B6 (en) 2001-02-14
HU9603372D0 (en) 1997-01-28
HK1000877A1 (en) 2001-11-02
FI964897A0 (en) 1996-12-05
US6514993B1 (en) 2003-02-04
SK281646B6 (en) 2001-06-11
US20030120070A1 (en) 2003-06-26
AU2732295A (en) 1996-01-04
EP0770066B1 (en) 2000-05-17
BR9507930A (en) 1997-11-18
CN1067057C (en) 2001-06-13
NO965183D0 (en) 1996-12-04
ZA954688B (en) 1996-01-29
NO308534B1 (en) 2000-09-25
MX9605863A (en) 1998-06-30
CA2192113A1 (en) 1995-12-14
NZ288180A (en) 1998-07-28
SK154996A3 (en) 1997-08-06
HUT76470A (en) 1997-09-29
RU2140920C1 (en) 1999-11-10
PT770066E (en) 2000-11-30
PL180847B1 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
EP0770066B1 (en) Serotonin 5-ht 1a and dopamin d2 receptor ligands
US5585378A (en) Composition containing an oxoindole compound
USRE34299E (en) 1-(4&#39;-fluorophenyl)-3,5-substituted indoles useful in the treatment of psychic disorders and pharmaceutical compositions thereof
AU637991B2 (en) Novel piperazinyl derivatives
FR2501690A1 (en) HETEROCYCLIC DERIVATIVES OF THE 1,2,4-TRIAZOLE TYPE, THEIR PREPARATION AND THEIR PHARMACOLOGICAL APPLICATION
US6767907B2 (en) 4-aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
EP0029707B1 (en) Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
JP3898219B2 (en) Phenylindole compounds
WO1998031669A1 (en) Novel arylpiperazine derived from piperidine as antidepressant medicines
US6743808B1 (en) 4-aryl-1-(indanmethyl, dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) tetrahydropyridines or piperazines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95194369.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2192113

Country of ref document: CA

Ref document number: 154996

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 964897

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: PV1996-3589

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 09424930

Country of ref document: US

Ref document number: 1019960707006

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 288180

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995922420

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995922420

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1996-3589

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1995922420

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV1996-3589

Country of ref document: CZ